Invest in Fisher Wallace

We Expect This To Be Our Last Equity Crowdfunding Campaign (followed by venture capital)

Bonus Shares Offered Until April 3rd Only:

  • 100% Bonus Shares for Returning Investors
  • 75% Bonus Shares for First-Time Investors
  • Minimum Purchase for Bonus Shares: $299.85
  • Investors Who Don’t Already Have an OAK Coupon Will Receive One With An Investment of ≥$999.50

INVEST NOW

Share Price: $11.11
(Includes 3.5% processing fee)

Offering Circular | FORM C | Investor Education


 

 

Our Recent Momentum

  • Our Seattle Police Department anxiety study achieved its primary endpoint – a groundbreaking result for improving First Responder mental health. These results will be used to apply for new FDA clearance for the treatment of anxiety.
     
  • Dr. Maurizio Fava, Psychiatrist-in-Chief of Massachusetts General Hospital and Associate Dean for Clinical and Translational Research at Harvard Medical School, joined Fisher Wallace as an advisor to design and help implement a 12-week pivotal trial to obtain FDA approval for the treatment of depression.
     
  • Former US Secretary of Veterans Affairs, Dr. David Shulkin, joined Fisher Wallace as an advisor to help guide our VA reimbursement and distribution strategy.
     
  • Our Alzheimer’s research Letter of Intent was accepted by the Alzheimer’s Drug Discovery Foundation. A full proposal is due by July 22nd. Nalaka Gooneratne, Associate Professor of Medicine at the University of Pennsylvania, is attached as Principal Investigator and drafting the protocol.


 

No Other Wearable Works Faster

The results of our recent research position our technology as the first self-administered depression and anxiety treatment proven to be effective in the first week.



 

We Must Increase Access to Care

By leveraging telemedicine and shipping logistics to make our technology immediately available to patients, and by scaling insurance reimbursement, we can build a near future in which anyone who needs rapid depression or anxiety treatment can get it.



 

Designed for Generations

Gen Alpha and Gen Z have the highest prevalence of depression and anxiety. They also adopt new technologies more rapidly than older generations. This is why we collaborated with Eric Fields, the industrial designer behind Beats and Nest, to transform our medical technology into a brilliant consumer experience.


 

For Veterans and First Responders

Dr. David Shulkin, the former US Secretary of Veterans Affairs and CEO of Beth Israel Medical Center, recently joined Fisher Wallace as an advisor to help guide our VA distribution and reimbursement strategy.

The breakthrough results of our Seattle Police Department anxiety study, as well as our published depression study results, will support our efforts to gain VA adoption and help us scale treatment to the more than 4 million First Responders in the US. If you are a First Responder and would like to recommend our technology for a pilot program with your organization, please contact us.


 

 

We Proved Product-Market-Fit

Under temporary FDA clearance, Fisher Wallace commercialized its proof-of-concept Version 1.0 device and began making mental health history:

  • 100K units sold
  • 14K prescribers
  • $40M in revenue
  • Medicaid reimbursement (MaineCare)

We expect as many as 60K Version 1.0 customers to upgrade to OAK upon its commercial release.



 

Path To Approval

Our recently completed anxiety study, conducted with the Seattle Police Department, achieved its primary endpoint and will be used to support a new FDA clearance and a CE Mark (European clearance) for the acute treatment of anxiety.

We are raising venture capital to fund a 12-week clinical trial designed by Dr. Maurizio Fava (Massachusetts General Hospital, Harvard Medical School) to obtain FDA approval for the treatment of Major Depressive Disorder (following FDA clearance for anxiety).



 

Obtainable Market by Year 5

US & Europe

SOM
Serviceable Obtainable Market

$1.6B

2% of SAM



 

Invest in Fisher Wallace Now!

Bonus Shares Offered Until April 3rd Only:

  • 100% Bonus Shares for Returning Investors
  • 75% Bonus Shares for First-Time Investors
  • Minimum Purchase for Bonus Shares: $299.85
  • Investors Who Don’t Already Have an OAK Coupon Will Receive One With An Investment of ≥$999.50

INVEST NOW

 


 


 

Frequently asked questions

1. Why invest in startups?

Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise – you are buying a piece of a company and helping it grow.

2. How much can I invest?

Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.

3. How do I calculate my net worth?

To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.

4. What are the tax implications of an equity crowdfunding investment?

We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.

5. Who can invest in a Regulation CF Offering?

Individuals over 18 years of age can invest.

6. What do I need to know about early-stage investing? Are these investments risky?

There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.

7. When will I get my investment back?

The Common Stock (the “Shares”) of Fisher Wallace Laboratories (the “Company”) are not publicly-traded. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure.

8. Can I sell my shares?

Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions.

9. Exceptions to limitations on selling shares during the one-year lockup period:

In the event of death, divorce, or similar circumstance, shares can be transferred to:
• The company that issued the securities
• An accredited investor
• A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships)

10. What happens if a company does not reach their funding target?

If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.

11. How can I learn more about a company’s offering?

All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.

12. What if I change my mind about investing?

You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email:

13. How do I keep up with how the company is doing?

At a minimum, the company will be filing with the SEC and posting on it’s website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.

14. What relationship does the company have with DealMaker Securities?

Once an offering ends, the company may continue its relationship with DealMaker Securities for additional offerings in the future. DealMaker Securities’ affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends.



Discussion


By submitting your email address you confirm you are over 21 and agree to the Fisher Wallace Privacy Policy.

 

Contact Us

Fisher Wallace Laboratories
630 Flushing Avenue, Suite 104
Brooklyn, NY 11206

Phone: 800.692.4380
Email: investors@fisherwallace.com


Information Relating to the Offering:

All Investors will receive the highest single bonus for which they are eligible. To receive perks from an investment in this offering, an investor must submit a single investment in this offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed. OAK® coupon codes will be given to new investors (someone having never previously invested in Fisher Wallace) that meet the required investment threshold. Additionally, existing investors that have not previously received an OAK® coupon code in prior offerings are eligible to receive one if they meet the required investment threshold.

We are completing the design phase of the Fisher Wallace Version 2 Device and are seeking FDA approval, and expect to commence manufacturing in late 2024 and distribute investigational devices for usability testing, confirmatory testing, and pilot studies prior to commercially distributing the device under regulatory approval; provided, however, there may be design and production delays which may extend the delivery date. In addition, we may not successfully complete the design and manufacturing or obtain necessary FDA approvals for the product, in which case the device may never be delivered. We, therefore, assign no value to this coupon.

Days 1-7 include the day this offering is launched (the "Launch Date") through 3:00pm Eastern Daylight Time ("EDT") (07:00 pm UTC) on the 7th day following the Launch Date. Days 8-21 commence at 3:00pm EDT (07:00 pm UTC) on the 7th day following the Launch Date, and ends at 3:00 pm EDT (07:00 pm UTC) on the 21st day following the Launch Date.

PERK RELATED DISCLAIMER:

There is no guarantee that OAK will be manufactured or that regulatory permission (such as FDA approval or clearance) that may be required to distribute OAK commercially will be granted. At the current time, there are neuromodulation devices intended for wellness that are commercially available without a prescription and are not regulated as medical devices, however the regulatory and prescription requirements for such devices may change. Regulatory permission to distribute OAK, should it be granted, may not be granted until late 2024 or 2025, and if granted, a prescription may be required to obtain OAK.

OFFERING DISCLAIMER:

Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Any past performance described is not indicative of future results. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.

DealMaker Securities LLC, a registered broker-dealer, and member of http://www.finra.org/ | http://www.sipc.org/, located at 4000 Eagle Point Corporate Drive, Suite 124, Birmingham, AL 35242., is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA's https://brokercheck.finra.org/firm/summary/315324.

DealMaker Securities LLC does not make investment recommendations.

DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer.

DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor's documentation for this investment.

DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing.

DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself.

Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor’s submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.

This website contains forward-looking statements. These statements may include the words “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate”, “project”, “will”, “may”, “targeting” and similar expressions as well as statements other than statements of historical facts including, without limitation, those regarding the financial position, business strategy, plans, targets and objectives of the management of Fisher Wallace (the "Company") for future operations (including development plans and objectives). Such forward-looking statements involve known and unknown risks, uncertainties and other important factors which may affect the Company's ability to implement and achieve the economic and monetary policies, budgetary plans, fiscal guidelines and other development benchmarks set out in such forward-looking statements and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future policies and plans and the environment in which the Company will operate in the future. Furthermore, certain forward-looking statements are based on assumptions or future events which may not prove to be accurate, and no reliance whatsoever should be placed on any forward-looking statements in this presentation. The forward-looking statements in this website speak only as of the date of the Company's initial Form C, and the Company expressly disclaims to the fullest extent permitted by law any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.